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Abstract High-risk human papillomavirus (hrHPV) is an es-
sential cause of cervical carcinoma and is also strongly related
to anal cancer development. The hrHPVE6 oncoprotein plays a
major role in carcinogenesis. We aimed to evaluate the frequen-
cy of hrHPVDNA and E6 oncoprotein in the anuses of women
with cervical carcinoma.We analyzed 117womenwith cervical
cancer and 103 controls for hrHPVand the E6 oncogene. Pos-
itive test results for a cervical carcinoma included 66.7 % with
hrHPV-16 and 7.7 % with hrHPV-18. One case tested positive
for both HPV variants (0.9 %). The samples from the anal canal
were positive for HPV-16 in 59.8 % of the cases. Simultaneous
presence of HPV in the cervix and anal canal was found in
53.8 % of the cases. Regarding expression of E6 RNA, posi-
tivity for HPV-16 in the anal canal was found in 21.2 % of the
cases, positivity for HPV-16 in the cervix was found in
75.0 %, and positivity for HPV-18 in the cervix was found
in 1.9 %. E6 expression in both the cervix and anal canal was
found in 19.2 % of the cases. In the controls, 1 % tested
positive for HPV-16 and 0 % for HPV-18. Anal samples from
the controls showed a hrHPV frequency of 4.9 % (only
HPV16). The presence of hrHPV in the anal canal of women
with cervical cancer was detected at a high frequency. We also
detected E6 RNA expression in the anal canal of women with
cervical cancer, suggesting that these women are at risk for
anal hrHPV infection.
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Background
Persistent infection with high-risk human papillomavirus
(hrHPV) is strongly associated with the development of gy-
necological and non-gynecological cancers [1, 2]. Cervical
cancer has been studied extensively, and it has been
established that hrHPV infection is a significant cause of cer-
vical carcinogenesis [3]. Current HPV testing, vaccinations,
and cytology examination are expected to enhance the quality
of cervical cancer prevention programs [4]. Well-conducted
screening programs are recognized as efficient instruments
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for preventing cervical cancer, but the efficacy of these initia-
tives varies based on the public health systems in place in
different countries. Socioeconomic factors, including devel-
oped medical and social infrastructures, accessible laboratory
facilities, and professional human resources, play a significant
role in the effectiveness of screening efforts. Unfavorable con-
ditions in poor and developing countries make screening chal-
lenging, and HPV vaccination may represent an alternative
approach to effectively reduce the burden of HPV-related can-
cer [5]. Concomitant hrHPV infections in the uterine cervix
and anal canal are associated with different risk factors that
can increase the risk of HPV-induced cancer development;
importantly, high incidences of anal hrHPV infection have
been associated with cervical lesions [6]. Although anal
hrHPV infection is a source for hrHPV cervical re-infection,
there are notable biases [7]. Due to the numerous discrepan-
cies and differences in variables assessed in previous studies,
it is difficult to determine the true cause of anal and cervical
concomitant HPV infection. In males, this association is re-
markably high in men who have sex with men and persistent
in patients infected with the human immunodeficiency virus.
The likely auto-contamination and differences in HPVassays
also interfere with establishing the cause of simultaneous HPV
infection of the cervix and anus [7].
We investigated the prevalence of HPV in the anal canal
in a small group of women with grade 3 biopsy-proven
cervical intraepithelial neoplasia (CIN3). We compared the
HPV frequency, using Hybrid Capture2™ technology,
among 40 women with CIN3 and 40 women with normal
results from colposcopic examinations and Pap tests. Of the
women with CIN3, 39 (97.5 %) tested positive for HPV in
the uterine cervix, and 14 (35 %) tested positive in the anal
canal; interestingly, four women in the control group (10 %)
tested positive for HPV in both the cervix and the anus.
Despite the small sample size, the prevalence of HPV in
the anal canal was significantly greater in women with
CIN3 than in controls [8].
Objectives
In this context, the current study sought to evaluate the fre-
quency of hrHPV DNA and E6 oncoprotein expression in a
larger, biopsy-proven group of women with carcinomas of the
cervix and determine whether there was any correlation with
the presence or absence of hrHPV in anal samples.
Materials and methods
A cross-sectional study was conducted in womenwith biopsy-
proven carcinoma of the cervix who were outpatients at the
gynecology department, and the control group comprised
women recruited from the Prevention Department of Founda-
tion Pius XII (Cancer Hospital of Barretos—SP) between Feb-
ruary 2010 and February 2012. Eligible subjects were females
aged 18 years or older. All participants provided informed
consent, and the ethics committee approved the study.
We analyzed the following two groups of women: the
cases, which comprised 117 women with cervical tumors,
and the controls, which comprised 103 women without gyne-
cological abnormalities or colposcopic or cytological alter-
ations. We collected biopsies from the cervix and brushed
cytological samples from the cervical and anal canals from
the cases to test for hrHPV DNA and expression of the HPV
E6 oncoprotein. We also obtained brushed samples from the
cervical and anal canals of the controls but did not perform
biopsies. All brushed materials were stored at −20 and −80 °C
for the subsequent extraction of DNA and RNA, respectively.
Both groups underwent blood sampling to test for the pres-
ence of HIV-1 and HIV-2.
Cervical sample collection
With the women in a gynecological position, and after
obtaining direct visualization of the cervix, a cytobrush device
was introduced (Rover, Netherlands) 1.0 to 1.5 cm into the
endocervical canal (when visible) until the largest bristles
touched the ectocervical region. The brush was then turned
clockwise five times. When the endocervical canal was not
accessible, samples were collected from the surface of the
tumor. The samples were immediately placed in a preservative
solution.
Anal canal sample collection
To collect material from the anal canal, the women remained
in the same position, the examiner’s gloves were changed, and
a different brush was introduced into the anal canal. This
brush was placed 3.0 cm anterior to the year-cutaneous line,
to ensure the dentate line had been reached. The brush was
turned clockwise five times, and the samples were immediate-
ly placed in a preservative solution.
The cell samples were subsequently placed into a tube con-
taining Tris-EDTA buffer (TE, 10 mM Tris–HCl and 1 mM
EDTA, pH 7.4) and centrifuged at 1000 rpm for 5 min. The
cell pellet was resuspended in 500 μLTE and divided into two
aliquots of 250 μL placed in 1.5-mL DNase/RNase-free
microfuge tubes (Axygen, Union City, CA, USA). One ali-
quot was stored at −80 °C and the other at −20 °C to preserve
the samples for RNA and DNA extraction, respectively.
DNA extraction
DNA was extracted from fresh samples and from samples
preserved in an in-house buffered methanol-based
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solution material using a QIAamp DNA Mini Kit and
QIAamp DNA Micro Kit (Qiagen, Biotecnologia do Bra-
sil Ltda), respectively, according to the manufacturer’s
instructions. The DNA elution volume at the end of the
extraction process was 200 μL.
E7 HPV-16/HPV-18 type-specific real-time PCR
The samples were submitted to a type-specific TaqMan-
based real-time qPCR assay targeting HPV16/HPV18 E7.
The qPCR assays were performed in an ABI 7300 Real-
Time PCR System (Applied Biosystems, Foster City,
CA). All samples and controls were run in duplicate.
The HPV16 E7 qPCR assays included the following oli-
gonucleotide primers: forward (5′GATGAAATAGATGG
TCCAGC3′) and reverse (5′GCTTTGTACGCACAAC
CGAAGC3′) primers, [9] and a probe (5′FAM-CAAG
CAGAACCGGACAG-MGB-NFQ). In a final reaction
volume of 25 μL, each qPCR reaction contained 1X
TaqMan master mix (Applied Biosystems, Foster City,
CA), 400 nM each of the forward and reverse primers,
200 nM of fluorogenic TaqMan probe, and 5 μL of ex-
tracted DNA. The amplification conditions consisted of
50 °C for 2 min and 95 °C for 10 min, followed by
40 cycles of 95 °C for 15 s, 55 °C for 1 min, and 60 °C
for 1 min. Each qPCR run included the following con-
trols: (i) SiHa cell line DNA (harboring 1–2 copies/cell
of HPV16) and (ii) water as a negative control. The
HPV18-E7 qPCR assays included the following oligonu-
cleotide primers: forward (5′AAGAAAACGATGAAAT
AGATGGA3′) and reverse (5′ GGCTTCCACCTTACAA
CACA3′) primers, [9] and a probe (5′VIC-AATCATCA
ACATTTACCAGCC-MGBNFQ3′). In a final reaction
volume of 25 μL, each qPCR contained 1X TaqMan mas-
ter mix (Applied Biosystems, Foster City, CA), 400 nM
each of the forward and reverse primers, 400 nM
fluorogenic TaqMan probe, and 5 μL extracted DNA.
The amplification conditions consisted of 50 °C for
2 min and 95 °C for 10 min, followed by 40 cycles of
95 °C for 15 s, 50 °C for 1 min, and 60 °C for 1 min. The
qPCR was performed using an ABI 7300 machine, and
each run included the following controls: (i) HeLa cell
line DNA (harboring 20 copies/cell of HPV18) and (ii)
water as a negative control.
General standards for HPV identification
Real-time qPCR was standardized to detect HPV copies per
milliliter of plasma. To determine the analytical sensitivity,
six replicates for each point of the standard curve were sub-
jected to the standard assay. For construction of the standard
curve, DNA extracted from Caski and HeLa cells was used.
To construct the standard curve for HPV-16, DNA extracted
from Caski cells was used at a concentration of 50 ng. Ini-
tially, 10 μL of DNA extracted from Caski cells were added
to 1 mL of negative plasma. Given that one diploid cell has
6.6 pg of DNA, and cells in the Caski cell line have 600
copies of HPV-16 per cell, we know that 4.5×107 copies of
HPV-16 were added in 1 mL of negative plasma. Subse-
quently, serial dilutions were made up to a concentration
of 4.5×101 HPV-16 copies. To construct the standard curve
for detection of HPV-18 reactions, the same procedure was
adopted. Initially, 10 μL of the DNA extracted from HeLa
cells at a concentration of 30 ng/μL were added to 1 mL of
negative plasma. Given that one diploid cell has 6.6 pg of
DNA and cells in the HeLa cell line have 20 copies of HPV-
18 per cell, we know that 9.1×105 copies of HPV-18 were
added in 1 mL of negative plasma. Subsequently, serial di-
lutions were made up to a concentration of 9.1×101 HPV-18
copies. To ascertain the analytical specificity of the PCR
reaction using standard real-time methodology, we subjected
the DNA of the tumor samples that tested positive for dif-
ferent types of HPV (16, 18, 31, 33, 35, 45, 58, 39, 73, 68,
6, 11, 42, 44, and 51) to specific reactions for HPV-16 and
HPV-18. The alignment of the primers and probes of the E7
region of HPV 16 sequences was carried out for different
types of HPV, obtained from GenbankGenBank, to confirm
the presence of mismatches, and all had at least one or more
mismatches. We also performed a second test to evaluate
real-time qPCR specificity using 20 plasma samples from
healthy pregnant women in whom detection of the presence
of viral DNA was not expected. All 20 samples tested neg-
ative for both HPV 16 and HPV 18.
Human β-globin PCR
β-globin PCR was performed as previously described in the
literature [10].
RNA analysis
RNA assays were performed on the samples preserved
with a buffered methanol-based solution prepared in our
lab. RNA extraction was performed using the RNeasy
Mini Kit (Qiagen, JP) according to the manufacturer’s
protocol. The samples were initially found to have low
levels of RNA; therefore, a TRIzol extraction was per-
formed to obtain higher levels of RNA. However, the
RNA quantity remained low and we opted to extract
RNA from all samples with TRIzol. QuantiTec Whole
Transcriptome Kits (Qiagen, JP) were used to increase
the levels of RNA for conversion into cDNA. After this
process, real-time PCR was performed using plates for the
device, the E6 primers, and Platinum SYBR Green
(Invitrogen).
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Ethics
All women enrolled in this study signed an informed consent
form. The study protocol was approved by the Barretos Can-
cer Hospital Ethics Committee.
Statistical analysis
Data were analyzed using SPSS for Windows® version
20.0 (Inc., Chicago, IL, USA). A Student’s t test was used
to compare the means of quantitative variables between
the two groups. To analyze the association between
groups and qualitative variables in the study, we used a
Fisher’s exact test. To evaluate the association between
related groups (more than one measurement per patient),
we used the McNemar test. We adopted the significance
level of 5 % for all analyses.
Results
A total of 117 women with cervical tumors and 103 wom-
en without cervical lesions were enrolled in this study.
The detailed characteristics of the control and case groups
are listed in Table 1. Anal intercourse, tobacco consump-
tion, and alcohol consumption were not significantly dif-
ferent between the groups. However, the control and case
groups showed significant differences in skin color
(<0.001), education level (<0.001), and marital status
(<0.003). In addition, the mean age was higher in the
cases than the controls (Table 2). The age at first sexual
intercourse, age at menarche, and number of sexual part-
ners were not significantly different between the two
groups. However, the number of births was greater in
the cases (<0.001).
Table 3 shows the significant differences in the frequency
of hrHPV detection in the control and case groups, according
to cervical and anal regions. The rates of positive hrHPV tests
in the anal canal were significantly different between groups
(<0.001); HPV16 was significantly more prevalent in the anal
canal samples of women diagnosed with cervical cancer when
compared to controls (<0.001). Two cases of HPV18 were
detected in the anal canals of women with cervical cancer
(p=0.500).
Regarding the uterine cervix tests, hrHPV was detected in
only 1 % of the women in the control group, and this rate was
significantly higher in the cases (75.3 %; p<0.001). HPV16
was more prevalent in women with cervical cancer (<0.001),
Table 1 The number and percentage of patients included in the study, according to social and cultural variables
Variable Category Control group Case group p valuea
N (%) N (%)
Skin pigmentation White 37 (35.9) 77 (66.4) <0.001
Non-White 66 (64.1) 39 (33.6)
Education level Illiterate 1 (1.0) 15 (12.9) <0.001
Basic 46 (44.7) 73 (62.6)
High school 43 (41.7) 22 (19.0)
University 13 (12.6) 6 (5.2)
Marital status Single 23 (22.3) 12 (10.4) 0.003
Married/stable union 70 (68.0) 72 (62.6)
Divorced 6 (5.8) 15 (13.0)
Widowed 4 (3.9) 16 (13.9)
Oral contraceptive
use (current)
No 85 (82.5) 109 (94.7) 0.005
Yes 18 (17.5) 6 (5.3)
Tobacco (current) No 88 (85.4) 97 (84.3) 0.852
Yes 15 (14.6) 18 (15.7)
Alcoholism (current) No 96 (93.2) 108 (95.6) 0.558
Yes 7 (6.8) 5 (4.4)
Anal intercourse No 97 (94.2) 102 (89.5) 0.229
Yes 6 (5.8) 12 (10.5)
Histology (Squamous) In situ – – 3 (2.6) NA
Invasive, SCC – – 97 (82.9)
Invasive, AdenoCA – – 17 (14.5)
NA not applicable
a Fisher exact test
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with positive test results in almost 67 % of cases. HPV18 tests
were positive in nine women in the case group (7.7%), where-
as only one case of HPV16 was found in women from the
control group. Simultaneous HPV16 and HPV18 infection
was found in the anal canal and cervix in one woman in the
case group. Finally, positive hrHPV tests were found in both
the uterine cervix and anal canal samples of 63 (53.8 %) wom-
en with cervical carcinoma but no positive results were found
in the control samples (<0.001).
E6 RNA analysis for HPV16 and HPV18 was per-
formed exclusively in samples from women with cervi-
cal cancer, and material for analysis was available in 52
Table 2 Themean values (and standard deviations) of variables related to the women’s age, reproductive history, and age at the first sexual intercourse
according to the presence or absence of cervical cancer
Variable Control group Case group p
valuea
Age (years) N 103 117 <0.001
Mean (sd) 44.8 (11.2) 53.1 (15.8)
Age at first sexual
intercourse (age)
N 101 114 0.162
Mean (sd) 18.6 (4.7) 17.8 (3.8)
Menarche (years) N 101 115 0.489
Mean (sd) 13.1 (1.6) 12.9 (1.8)
Number of sexual
partners
N 101 114 0.113
Mean (sd) 1.9 (2.3) 2.4 (2.7)
Number of births N 102 115 <0.001
Mean (sd) 2.5 (1.9) 4.1 (2.8)
sd standard deviation
a Student’s t test
Table 3 The number and percentage of women according to HPV status, the expression of E6 oncoprotein, and the presence or absence of a cervical
tumor
Variable Category Control group Case group p valuea
N (%) N (%)
HPV—anal canal Negative 98 (95.1) 46 (39.3) <0.001
HPV16 5 (4.9) 69 (59.8)
HPV18 0 (0.0) 1 (0.9)
HPV16+HPV18 0 (0.0) 1 (0.9)
HPV—uterine cervix Negative 101 (99.0) 29 (24.8) <0.001
HPV16 1 (1.0) 78 (66.7)
HPV18 0 (0.0) 9 (7.7)
HPV16+HPV18 0 (0.0) 1 (0.9)
HPV simultaneously in No 103 (100.0) 54 (46.2) <0.001
the uterine cervix and anal canal Yes 0 (0.0) 63 (53.8)
E6 (HPV16)—canal anal Negative – – 41 (78.8) NA
Positive – – 11 (21.2)
E6 (HPV18)—canal anal Negative – – 52 (100.0) NA
Positive – – 0 (0.0)
E6 (HPV16)—cervix Negative – – 13 (25.0) NA
Positive – – 39 (75.0)
E6 (HPV18)—cervix Negative – – 51 (98.1) NA
Positive – – 1 (1.9)
E6 in cervix and anal canal simultaneously No – – 42 (80.8) NA
Yes – – 10 (19.2)
NA not applicable
a Fisher exact test
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of these cases (adequate RNA quality and concentra-
tion). Analysis of the anal canal samples resulted in
identification of 11 positive cases (21.2 %) of HPV16
E6 RNA and no positive cases of HPV18 E6 RNA.
Analysis of the uterine cervix samples indicated a pos-
itive result for HPV16 E6 RNA in 39 (75 %) cases and
a positive result for HPV18 E6 RNA in one (1.9 %)
case. Simultaneous detection of hrHPV RNA E6 in both
the cervical and anal samples was observed in 10 cases
(19.2 %).
Table 4 shows that women without cervical cancer
demonstrated similar rates of HPV in the uterine cervix
and anal canal (p=0.219). However, women with cervi-
cal lesions showed a higher frequency of hrHPV DNA
in both the anal and cervical regions compared to the
negative cases (p=0.005). The hrHPV E6 RNA was
expressed in the cervix and anal canal of the women
with cervical tumors and was more frequent in the cer-
vix (p<0.001).
Discussion
We found that a normal anal canal region may act as a reser-
voir for hrHPV infection in women with cervical carcinoma,
as 54 % of women with HPV-induced cervical tumors dem-
onstrated concomitant positive DNA-HPV tests. In contrast, a
very low frequency of hrHPV was found in the anal canals of
women without cervical lesions, which is consistent with pre-
viously published reports on women with cervical high-grade
lesions [8]. Importantly, HPV infection was shown to be more
common in HIV-infected women than uninfected women
[11], although all women tested negative for HIV in our study.
Positive tests for hrHPV were significantly associated with
cervical cancer, which is consistent with the alleged reservoir
role of the anal canal for hrHPV infection. Anal investigation
of hrHPVin patients with cervical cancer has been adjudicated
because of the augmented risk of HPV-induced lesion
recurrence. Asmentioned previously, the anal canal may serve
as a reservoir for subclinical HPV in cases of cervical carci-
noma; consequently, it is justifiable to test for anal hrHPV in
patients with cervical tumors [6, 7]. HPVautoinoculation from
the cervix to the anus or vice-versa is common; however, the
duration of this reservoir of HPV is largely unknown, mainly
because the clearance of anal HPV infection is frequent [7].
The assessment of concomitant anal and cervical HPV in-
fection using DNA assays is relatively common, although few
studies have included RNA-targeted tests. The detection of
HPV RNA is believed to be a prognostic parameter due to
its potential value as a marker for lesion progression [12].
Moreover, a positive test for RNA is thought to be related to
the progression of HPV-induced disease, involving
oncoprotein production and the activation of a molecular cas-
cade of cellular alterations. However, RNA-based tests are
typically less sensitive than DNA tests for the identification
of HPV [12]. This was confirmed in our study, as the RNA
investigation detected an almost threefold lower hrHPV fre-
quency compared to the DNA assay (<0.001). There may be a
number of reasons for this significant difference, although the
most likely reasons include reduced integrity of RNA and the
technical difficulties involved in standardizing an RNA assay
in fresh and fixed materials [13]. Different results have been
reported regarding the performance of commercially available
molecular assays kits for HPVDNA and RNA, although these
generally provide superior specificity for RNA and higher
sensitivity for DNA [14–16].
Of note, the high frequency of concomitant HPV16
infection in both the anal canal and uterine cervix cor-
roborates data from previous studies [12, 17]. For ex-
ample, heterosexual women with cervical HPV infection
were shown to be at risk of concomitant, same-type
anal hrHPV infection [17], and another recent report
documented the exclusive association of low-risk
HPV6 and HPV11 in anal high-grade lesions [18].
However, our study was limited because we only eval-
uated HPV16 and HPV18, which have been recognized
Table 4 The number and percentage of womenwith andwithout cervical lesions distributed according to hrHPVDNAand E6 hrHPVRNA in the anal
and cervical regions
Group Variable Category Anal
canal
Uterine
cervix
p
valuea
N (%) N (%)
Without cervical
cancer
HPV (16 or 18) Negative 97 (95.1) 101 (99.0) 0.219
Positive 5 (4.9) 1 (1.0)
With cervical
cancer
HPV (16 or 18) Negative 46 (39.3) 29 (24.8) 0.005
Positive 71 (60.7) 88 (75.2)
E6 Negative 41 (78.8) 12 (23.1) <0.001
Positive 11 (21.2) 40 (76.9)
aMcNemar test
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as the most prevalent forms of HPV in the cervical and
anal regions [19].
The HPV vaccine has great potential for preventing lower
genital tract cancer and precursor lesions. The effect of this
vaccine on the prevention of anal cancer and anal HPV infec-
tion has also been explored, as well as reducing the rates of
anal high-grade intraepithelial neoplasia among the group of
men who have sex with men [20]. The identification of the
specific types of HPV involved in anal infection and the risk
factors for anal HPV infection and dysplasia may provide
insight into the potential efficacy of the HPV vaccine in
preventing anal intraepithelial lesions and anal cancer in
high-risk groups of women [20]. Further studies should eval-
uate the potential usefulness of the HPV vaccine in preventing
not only cervical cancer and precursor lesions but also all
HPV-related lesions of the anogenital tract.
Funding We acknowledge the Research Support Fund of the State of
São Paulo (FAPESP), process number 2010/16795–4), for the financial
support grants. FAPESP had no other type of influence on this manuscript
beyond the financial support.
Conflicts of interest None
Ethical approval The study was approved by the Ethic Committee
number 310/2010, signed in 04 May 2010.
References
1. Préaud E, Largeron N. Economic burden of non-cervical cancers
attributable to human papillomavirus: a European scoping review. J
Med Econ. 2013;16:763–6.
2. Gillison ML, Castellsagué X, Chaturvedi A, et al. Comparative epi-
demiology of HPV infection and associated cancers of the head and
neck and cervix. Int J Cancer. 2013. doi:10.1002/ijc.28201.
3. Wheeler CM. The natural history of cervical human papillomavirus
infections and cervical cancer: gaps in knowledge and future hori-
zons. Obstet Gynecol Clin North Am. 2013;40:165–76.
4. Franco EL, de Sanjosé S, Broker TR, et al. Human papillomavirus
and cancer prevention: gaps in knowledge and prospects for research,
policy, and advocacy. Vaccine. 2012;30 Suppl 5:F175–82.
5. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F.
Worldwide trends in cervical cancer incidence: impact of screening
against changes in disease risk factors. Eur J Cancer. 2013;49:3262–
73.
6. Valari O, Koliopoulos G, Karakitsos P, et al. Human papillomavirus
DNA and mRNA positivity of the anal canal in women with lower
genital tract HPV lesions: predictors and clinical implications.
Gynecol Oncol. 2011;122:505–8.
7. Moscicki AB, Schiffman M, Burchell A, et al. Updating the natural
history of human papillomavirus and anogenital cancers. Vaccine.
2012;30 Suppl 5:F24–33.
8. Véo CA, Saad SS, Nicolau SM, Melani AG, Denadai MV. Study on
the prevalence of human papillomavirus in the anal canal of women
with cervical intraepithelial neoplasia grade III. Eur J Obstet Gynecol
Reprod Biol. 2008;140:103–7.
9. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillo-
mavirus is a necessary cause of invasive cervical cancer worldwide. J
Pathol. 1999;189:12–9.
10. Saiki R, Scharf S, Faloona F, et al. Enzymatic amplification of beta-
globin genomic sequences and restriction site analysis for diagnosis
of sickle cell anemia. Science. 1985;230:1350–4.
11. Hessol NA, Holly EA, Efird JT, et al. Concomitant anal and cervical
human papillomavirus infections and intraepithelial neoplasia in
HIV-infected and uninfected women. AIDS. 2013;27:1743–51.
12. Broccolo F, Fusetti L, Rosini S, et al. Comparison of oncogenic HPV
type-specific viral DNA load and E6/E7 mRNA detection in cervical
samples: results from a multicenter study. J Med Virol. 2013;85:472–
82.
13. Staff S, Kujala P, Karhu R, et al. Preservation of nucleic acids and
tissue morphology in paraffin-embedded clinical samples: compari-
son of five molecular fixatives. J Clin Pathol. 2013;66:807–10.
14. Castle PE, Follansbee S, Borgonovo S, et al. A comparison of human
papillomavirus genotype-specific DNA and E6/E7 mRNA detection
to identify anal precancer among HIV-infected men who have sex
with men. Cancer Epidemiol Biomarkers Prev. 2013;22:42–9.
15. Waldstrom M, Ornskov D. Comparison of the clinical performance
of an HPV mRNA test and an HPV DNA test in triage of atypical
squamous cells of undetermined significance (ASC-US).
Cytopathology. 2012;23:389–95.
16. Szarewski A, Mesher D, Cadman L, et al. Comparison of seven tests
for high-grade cervical intraepithelial neoplasia in women with ab-
normal smears: the Predictors 2 study. J Clin Microbiol. 2012;50:
1867–73.
17. Guler T, Uygur D, Uncu M, et al. Coexisting anal human papilloma
virus infection in heterosexual women with cervical HPV infection.
Arch Gynecol Obstet. 2013;288:667–82.
18. Cornall AM, Roberts JM, Garland SM, Hillman RJ, Grulich AE,
Tabrizi SN. Anal and perianal squamous carcinomas and high-
grade intraepithelial lesions exclusively associated with Blow-risk^
HPV genotypes 6 and 11. Int J Cancer. 2013;133:2253–8.
19. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-
related cancers among men and women. J Adolesc Health.
2010;46(4 Suppl):S20–6.
20. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against
anal HPV infection and anal intraepithelial neoplasia. N Engl J Med.
2011;365:1576–85.
Tumor Biol.
